Review of Contemporary Techniques for Minimally Invasive Coronary Revascularization

Ali Fatehi Hassanabad1*, MD MSc, Jimmy Kang2*, BSc, Andrew Maitland1, MD, Corey Adams1, MD MSc, and William D. T. Kent1, MD MSc

Abstract
Minimally invasive coronary revascularization techniques aim to avoid median sternotomy with its associated complications, while facilitating recovery and maintaining the benefits of surgical revascularization. The 3 most common procedures are minimally invasive coronary artery bypass grafting, totally endoscopic coronary artery bypass, and hybrid coronary revascularization. For a variety of reasons, including cost and technical difficulty, not many centers are routinely performing minimally invasive coronary revascularization. Nevertheless, many studies have assessed the safety and efficacy of each of these procedures in different clinical contexts. Thus far results have been promising, and with the evolution of procedural techniques, these approaches have the potential to redefine coronary revascularization in the future. This review highlights the current state of minimally invasive coronary revascularization techniques by exploring their benefits, identifying barriers to their adoption, and discussing future potential paradigms.

Keywords
minimally invasive surgery, coronary artery bypass surgery, hybrid revascularization, clinical outcomes

Introduction
Current guidelines for the treatment of coronary artery disease (CAD) suggest coronary artery bypass grafting (CABG) as the gold standard revascularization strategy for multivessel and left main CAD.1-3 The guidelines have largely been influenced by large, important clinical trials, such as SYNTAX and FREEDOM,4,5 which have firmly established the advantage of CABG over percutaneous coronary intervention (PCI), particularly in an environment of increasingly complex CAD, obesity, and diabetes. Recent trials, such as Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease (EXCEL Trial)6 and Nordic-Baltic-British left main revascularization study (NOBLE Trial)7 have reconfirmed CABG superiority over PCI in survival and freedom from adverse cardiovascular outcomes, resulting in a resurgence of CABG in North America.8,9 However, CABG performed via sternotomy remains a highly invasive procedure and, when given the choice, many patients still choose PCI for multivessel CAD, despite the fact that 1-year risk of death and risk of repeat procedures for PCI far exceeds that of CABG.10 Therefore, minimally invasive coronary revascularization techniques have been introduced to redefine surgical revascularization and address patient preference for a less invasive procedure, while maintaining the clinical outcome advantage of CABG over PCI.

Today, several minimally invasive CABG techniques have emerged with various degrees of robotic and video assistance, myocardial protection, graft usage, incision placement,
anastomotic techniques, endoballoon usage, and combination with PCI. Among these approaches, 3 minimally invasive coronary revascularization techniques are of note. Minimally invasive (MICS) CABG performed via a mini left anterior thoracotomy, totally endoscopic coronary artery bypass (TECAB) using robots, and hybrid coronary revascularization (HCR) combining the anastomosis of the left internal mammary artery (LIMA) to the left anterior descending artery (LAD) with PCI to non-LAD lesions. These approaches confer the benefits of MICS: avoidance of sternotomy, smaller incisions, shorter hospital stay, earlier recovery, decreased bleeding, less transfusion, and reduced risk of sternal infection. However, the uptake of minimally invasive coronary revascularization has been limited by barriers such as increased cost, lack of randomized controlled trials, technical difficulty, and, in some cases, lack of optimal surgical instruments. In this manuscript, we provide a thorough overview of the current state of minimally invasive coronary revascularization techniques, address challenges to their adoption, and discuss future outlooks.

**Minimally Invasive Coronary Artery Bypass Grafting**

**Overview**

MICS CABG was first introduced in 2005 by McGinn et al. as a modified version of minimally invasive direct vision coronary artery bypass (MIDCAB) from 1990. It still uses the left thoracotomy incision and a direct vision to perform the anastomoses, however, it is a more lateral and a smaller (4 to 6 cm) incision in the fifth intercostal space, which allows the LIMA to be harvested with less risk of costochondral or rib injury, although chest wall trauma may occur secondary to the heavy retractors needed to lift the anterior ribs in order to facilitate exposure of the ascending aorta. Its detailed operative technique is outlined in the literature. MICS CABG also allows for a multivessel coronary operation, unlike MIDCAB where the incision does not allow for a proximal anastomosis of the graft. A detailed approach for MIDCAB can be found here. Nonetheless, the term MIDCAB is still interchangeably used in the literature to describe a multivessel CABG procedure using left thoracotomy under direct vision.

**Outcomes**

Long-term clinical data on MICS CABG is limited, but several observational studies for MICS CABG have demonstrated promising clinical results. Studies have reported perioperative mortality rate at a range of 0%-1.3%, perioperative stroke rate from 0%-0.4%, and conversion rate from 0%-6.7%. Studies have also found decreased transfection, and lower surgical site infection rates with MICS CABG, and decreased hospital length of stay (LOS) and earlier return to full physical function in comparison to a sternotomy off-pump coronary artery bypass (OPCAB). The graft patency in MICS CABG was studied by Ruel et al. in 2014 where they showed complete revascularization in all 89 patients with 52.5% receiving >3 conduits and 92% patency for all grafts and 100% patency for LIMA at 6 months using computed tomography angiography. Nambiar et al. have also demonstrated an excellent outcome for MICS CABG using bilateral internal mammary arteries (BIMA) in 940 patients with 97.9% complete revascularization, 0.9% mortality, and 99.3% freedom from major adverse cardiac and cerebrovascular events (MACCE) at average follow-up of 33 months. From the group, 10 (1.06%) patients required reintervention, with 2 of them due to LIMA-RIMA Y anastomosis blockage. Although the reduced risk of sternal wound infection was mentioned in the paper, the number was not reported in their data.

The clinical benefits of MICS CABG shown in observational studies were challenged in the only randomized controlled trial (STET trial) conducted to date with 184 total patients. Although the patients in MICS CABG group in comparison to OPCAB group had reduced proinflammatory cytokines, reduced intubation time (256 vs 321 min), and fewer postoperative arrhythmias (23% vs 35%), MICS CABG had longer median hospital LOS (6 vs 5 days), and median operative time (4.1 vs 3.3 h). The 2 groups also had a similar pain score and quality of life scores at 3 months and 12 months. Others have postulated that the steep learning curve of the multivessel MICS CABG might have impacted the outcome of the trial. Another randomized trial comparing MICS CABG to conventional CABG called Minimally Invasive coronary surgery compared to STernotomy coronary artery bypass grafting (MIST Trial) is currently recruiting to assess quality of life and MACCE. A summary of MICS CABG studies is highlighted in Table 1.

**Patient Selection**

MICS CABG has been previously described to be performed on stable patients with preserved ventricular function unless cardiopulmonary bypass (CPB) is used. Absolute contraindications were listed as emergency surgery with hemodynamic compromise, severe chest deformities, and pulmonary comorbidities. A relative contraindication is patients with increased body mass index, as exposure through the thoracotomy may be restricted. The limitation in heart manipulation through a small left thoracotomy incision required preoperative assessment of distal coronary artery target quality to ensure adequate anastomosis. Diffuse and intramyocardial vessels were deemed unsuitable for MICS CABG. MICS CABG showed potential in providing a favorable long-term outcome in patients over 75 in a study by Barsoum et al. where 5-year all-cause mortality for MICS CABG was reported to be lower than conventional sternotomy CABG at 19.7% and 47.7%, respectively. Similar results were found for patients younger than 75 years.
The technical difficulty, especially achieving multivessel revascularization with a MICS CABG, presents the greatest barrier to the widespread adoption of this technique. This approach is also challenging when attempting to expose the distal segment of the LIMA through the thoracotomy incision. Formalized initiation steps to an off-pump multivessel MICS CABG are described by Une et al. where surgeons sequentially increase vessel number with or without CPB assistance. Rodriguez et al. have also emphasized that surgeons should be a very experienced OPCAB surgeon via sternotomy before performing an off-pump MICS CABG. Therefore, MICS CABG uptake and training will likely be limited to the institutions that routinely perform OPCAB procedures. With the CABG Off or On Pump Revascularization Study (CORONARY trial) showing no difference in clinical endpoints and identical survival at 5 years for both on-pump and off-pump CABG, centers that utilize the OPCAB technique will likely remain limited thereby restricting the number of surgeons to be trained in MICS CABG.

The learning curve of MICS CABG has been analyzed by Une et al. who showed no difference in clinical outcomes between the first 25 and the remainder for off-pump multivessel MICS CABG. However, there was a 14.5% conversion rate between the first 25 and the remainder for off-pump multivessel MICS CABG. Therefore, MICS CABG uptake and training will likely be limited to the institutions that routinely perform OPCAB procedures. With the CABG Off or On Pump Revascularization Study (CORONARY trial) showing no difference in clinical endpoints and identical survival at 5 years for both on-pump and off-pump CABG, centers that utilize the OPCAB technique will likely remain limited thereby restricting the number of surgeons to be trained in MICS CABG.

The STET trial showed a 10% increased hospital cost with MICS CABG versus OPCAB (£5,079 vs £4,566), which included £869 of reoperation cost for 4 patients in the MICS CABG group versus £0 in the OPCAB group. Finally, Merkle et al. reported higher costs associated with the MIDCAB group versus the PCI group in their analysis (10,879€ vs 4,009€).

Financial Summary

Table 1. Summary of Major MICS CABG Studies

| Authors                  | Patients | Follow-up time (mths) | Survival at follow-up | Freedom from stroke | Sternotomy conversion | Operative time (min) | LOS (days) | Number of grafts | Reintervention |
|--------------------------|----------|-----------------------|-----------------------|---------------------|-----------------------|----------------------|------------|-----------------|----------------|
| McGinn et al. (2009)     | 450      | 1                     | 98.7%                 | 99.6%               | 3.8%                  | N/A                  | 5.9 ± 3.4  | 2.1 ± 0.7       | 2.7%           |
| Lapierre et al. (2011)   | 150      | 3                     | 100%                  | 100%                | 6.3%                  | N/A                  | 5          | 1.8 ± 0.7       | 3.3%           |
| Rogers et al. (2013)     | 91       | 3 to 12               | 99%                   | 100%                | 2%                    | 246                  | 5          | N/A             | 4%             |
| Rabindranath et al. (2014) | 130     | 36                    | 100%                  | 99.2%               | 0.8%                  | 218.5                | 3.8        | 2.1             | 2.3%           |
| Zianku et al. (2015)     | 151      | 40.3                  | 99.3%                 | 100%                | 2.7%                  | 352.4 ± 74.4         | 4.5        | 2.9 ± 0.5       | N/A            |
| Rodriguez et al. (2017)  | 306      | 33.6                  | 100%                  | 100%                | 3.3%                  | N/A                  | 5.8 ± 5.5  | 1.8 ± 0.7       | 6.9%           |
| Nambiar et al. (2019)    | 940      | 2.9                   | 99.1%                 | 0.2%                | 0.6%                  | 173.8 ± 19.6         | 3.1 ± 1.2  | 3.2             | 1.1%           |

Abbreviations: LOS, length of stay; MICS CABG, minimally invasive coronary artery bypass grafting.

Barriers to Adoption

The greatest advantage of MICS CABG over other techniques is its ability to achieve multiarterial vessel grafting with BIMA without the associated risk of sternal wound infection, while keeping the operative cost relatively low. Studies exploring multiarterial grafting with MICS CABG are being conducted. Nambiar et al. have shown excellent clinical results with BIMA use, and Kikuchi et al. have shown the possibility of in situ RIMA harvesting and anastomosis with MICS CABG. However, to increase the number of cases, subsequent larger randomized trials need to demonstrate clear clinical benefit over conventional CABG that would justify the technical difficulty, which is the main disadvantage associated with multivessel MICS CABG.

Future Outlook

The greatest advantage of MICS CABG over other techniques is its ability to achieve multiarterial vessel grafting with BIMA without the associated risk of sternal wound infection, while keeping the operative cost relatively low. Studies exploring multiarterial grafting with MICS CABG are being conducted. Nambiar et al. have shown excellent clinical results with BIMA use, and Kikuchi et al. have shown the possibility of in situ RIMA harvesting and anastomosis with MICS CABG. However, to increase the number of cases, subsequent larger randomized trials need to demonstrate clear clinical benefit over conventional CABG that would justify the technical difficulty, which is the main disadvantage associated with multivessel MICS CABG.

Totally Endoscopic Coronary Artery Bypass

Overview

TECAB is a procedure performed entirely through trocar accesses without a surgical incision. It was first performed in Hôpital Broussai in Paris by Loulmet and colleagues in 1998. Since the initial enthusiasm to use robotics in cardiac surgery, its adoption has been limited to few dedicated centers around the world due to its barriers such as high cost, steep learning curve, evolving instrumentation, few training opportunities, and long procedural time. In the United States, 1,439 RA CABG procedures were performed in 2010 and the number dwindled to only 590 procedures in 2015. Similarly, in Europe,
173 RA CABG in 2001 declined to 80 procedures in 2015. While TECAB has been undergoing significant developments in robots and anastomotic techniques, it is still evolving where there is great potential for further major advances. Widespread adoption of this technique will depend on a few factors, including achieving economic and training feasibility and establishing clear clinical superiority over conventional CABG as demonstrated by large, multicenter, randomized controlled trials. Also, if there is going to be further and more widespread adoption of this technique, companies dedicated to TECAB should continue the innovative research and development process and ensure newer generation of devices receive approval from the appropriate regulatory bodies to facilitate their transition into clinical settings. Finally, TECAB is likely at least as technically difficult as MICS CABG. However, it may facilitate a less invasive procedure for a few reasons, including technological components can be present in the operative field instead of a keyhole view, the dexterity of the instruments, and ergonomics.

### Outcomes

The majority of TECAB studies in the literature reflect single-institution observational experiences with limitations in sample size and generalizability. The studies are also variable in their number of target vessels treated, anastomotic techniques (EndoWrist, Flex-A, U-clip), generation of da Vinci® robot used (da Vinci, da Vinci S, da Vinci Si; Intuitive Surgical, Sunnyvale, CA, USA) as well as CPB and endoballoon cardioplegia use as a stepping stone for overcoming learning curves. With newer technical advancements, there are improvements in conversion rates, operative time, and the impact of the learning curve on the outcome.37

The first meta-analysis on TECAB studies was conducted by Leonard et al. in 2018 with a total of 3,721 patients.38 Of the studies, 62.1% were arrested heart TECAB and 69.1% were single-vessel treatments. The meta-analysis showed a low operative mortality of 0.8%, and acceptable perioperative stroke and myocardial infarction (MI) rate of 1.5% and 2.3%, respectively. Long cross-clamp time, suboptimal myocardial protection, and increased cardiac biomarker checks could have caused the reported perioperative MI rates to rise in this meta-analysis.38 Similar clinical outcomes were noted in recent systematic reviews by Göbölös and Cao.37,39 Göbölös and colleagues analyzed a total of 2,397 TECAB cases with less than half being multivessel procedures. That study demonstrated an acceptable rate of perioperative mortality (0.8%) and perioperative major events such as stroke (1%), renal failure (1.6%), de novo atrial fibrillation (13.3%), and operative revision rate due to postoperative hemorrhage (4.2%). However, this cohort had both beating heart and arrested heart TECAB patients who underwent the subsequent hybrid procedure (16.8% and 30.3%, respectively), thus the data cannot be extrapolated as being purely a TECAB study.37 Cao and colleagues analyzed 9 beating heart TECAB studies with an average of fewer than 2 vessels bypassed. The results were similar in perioperative mortality rate (1.7%), perioperative MI rate (1.1%), stroke rate (1.1%), acute kidney injury rate (3.4%), and reoperation for bleeding rate (3.2%).39 The reported mortality rates of the above studies are lower than the FREEDOM trial with 1.7% and the SYNTAX trial with 3.5% at 1 year. Göbölös suspected this to be due to lower risk patients being chosen for this technically challenging procedure, despite only a small number of studies having performed formal risk evaluation. Summary of major TECAB studies is represented in Table 2.

Graft patency in TECAB was studied by Kitahara et al. in 2019 with 1,220 IMA grafts. They showed comparable patency rates of IMA grafts as in conventional CABG with 98.8%, 95.8%, and 93.6% at early (<1 month), midterm (<5 years), and}

### Table 2. Summary of Major TECAB Studies

| Authors                  | Types of surgery | Patients | Follow-up time (months) | Survival at follow-up | Freedom from MACCE | Sternotomy conversion | Operative time (min) | LOS (days) | BIMA use | Hybrid procedure |
|--------------------------|------------------|----------|-------------------------|-----------------------|--------------------|-----------------------|----------------------|-------------|-----------|------------------|
| De Cannière et al.       | Beating heart    | 111      | 6                       | 97.8%                 | 94.9%              | 33.3%                 | N/A                  | N/A         | 6%        | N/A              |
| Srivastava et al.        | Beating heart    | 108      | 11                      | 100%                  | 98.9%              | 5.5%                  | 273 ± 130            | 3.4 ± 2.0   | 36.5%     | 19.4%            |
| Bonatti et al. (2009)    | Arrested heart   | 100      | 72                      | 100%                  | 89%                | 11%                   | 272 (178 to 690)     | 6           | N/A       | 36%              |
| Srivastava et al. (2010) | Beating heart    | 241      | 24                      | 100%                  | 98.6%              | 11.2%                 | 177 ± 53             | N/A         | 27%       | N/A              |
| Balkhy et al. (2011)     | Beating heart    | 120      | 7                       | 99.2%                 | 97.5%              | 3%                    | N/A                  | 3.3 ± 2.4   | 16%       | 18%              |
| Dhawan et al. (2012)     | Beating heart    | 106      | 1                       | 96.2%                 | 78.3%              | 7%                    | 326 ± 139            | N/A         | 52%       | N/A              |
| Bonanos et al. (2013)    | Arrested heart   | 500      | 120                     | 99%                   | 95%                | 10%                   | 305 (112 to 1050)    | 6           | 22%       | 33%              |
| Weidinger et al. (2014)  | Arrested heart   | 384      | 60                      | 99.2%                 | 90%                | 14%                   | 275 (135 to 795)     | 7           | N/A       | 43%              |
| Yang et al. (2015)       | Beating heart    | 100      | 60                      | 100%                  | 97.1%              | N/A                   | 219 ± 58             | N/A         | 27%       | N/A              |
| Kitahara et al. (2018)   | Beating heart    | 263      | 1                       | 98.5%                 | 98.9%              | 3%                    | 286 ± 88             | 3.5 ± 2.9   | N/A       | N/A              |

Abbreviations: BIMA, bilateral internal mammary artery; LOS, length of stay; MACCE, major adverse cardiac and cerebrovascular events; TECAB, totally endoscopic coronary artery bypass.
long-term (>5 years) follow-up, respectively. \(^{40}\) A meta-analysis by Leonard et al. also revealed good short-term graft patency of 94.8% at mean follow-up of 10.1 months. \(^{38}\) Mean hospital LOS with TECAB in the 2 recent systematic reviews by Göbölös and Cao were reported as 5.6 and 5.8 days, which is not a drastic improvement compared to the conventional CABG. \(^{37,39}\) Göbölös also reported a shorter length of hospital stay of 4.7 days for beating heart TECAB in comparison to 6.6 days for arrested heart TECAB. Within the beating heart TECAB groups, studies with over 100 reported cases consistently showed short hospital LOS of 3.3 to 3.5 days. \(^{41-43}\)

RA CABG is not only bound to TECAB but to other techniques with various degree of robot utilization such as the minimally invasive RA direct coronary artery bypass (RADCAB) technique. RADCAB uses the robot to harvest the LITA and is followed by a manual anastomosis the graft to LAD using off pump techniques. Notably, Giambruno et al. have demonstrated excellent results with RADCAB with mortality rate of 0.3% with a graft patency of 92.7% at 95.8 months of follow-up duration. \(^{44}\)

**Patient Selection**

TECAB can target LAD, diagonal, ramus, and obtuse marginal branch, and the right coronary artery (RCA). The contraindications for TECAB are similar to that of MICS CABG: patients with hemodynamic instability, cardiogenic shock, severe chronic obstructive pulmonary disease (COPD), acute MI, and prior radiation to the chest. \(^{42}\) The clinical benefits of TECAB are best realized in treating high-risk patients for conventional CABG. Twenty-eight octogenarians (9.1%) who underwent TECAB were compared with younger patients in a study by Kitahara et al. where 60.7% were multivessel TECAB. They showed mean hospital LOS of 3.9 days with 78.6% being discharged home and no in-hospital mortality. \(^{40,45}\) These studies built on top of the previous work by Lee et al. which identified old age, hemodialysis, cerebrovascular accident, and higher risk scores as factors prolonging LOS following TECAB. \(^{46}\) Kitahara et al. also showed the beneficial outcome of TECAB for patients with body mass index >35, \(^{45}\) female patients, \(^{43}\) redo surgery, \(^{47}\) and high STS score. \(^{48}\)

In a study by Bonaros, TECAB also showed earlier functional recovery with the restoration of daily activities 2 to 3 weeks faster than conventional CABG, and significantly better quality of life scoring in physical health and bodily pain. \(^{49}\) Bonatti and colleagues also showed that patients with TECAB were able to return to household activities in 14 days, drive in 21 days, and perform sports in 42 days. \(^{50}\)

**Barriers to Adoption**

The cost of robotic cardiac surgery presents a major barrier to the wide adoption of TECAB and robotic cardiac surgery as a whole. The initial purchase price of a da Vinci robot is over 2 million USD and over 100,000 USD is required for maintenance fee. \(^{51,52}\) Cost analysis done by Pasrija found the median cost per TECAB patients to be $33,769 when compared to the RA-MIDCAB group of $22,679. \(^{31}\) This was significantly more expensive to Levyi’s cost analysis of conventional CABG at $18,601. \(^{53}\) Pasrija noted that $11,701 of the TECAB cost came from the stabilizer equipment while the operative cost was not significantly different when compared to RA-MIDCAB. \(^{31}\) The notion that the cost can be offset by the clinical benefits of TECAB remains speculative as no formal cost analysis has been conducted to date. Even if those clinical benefits are realized, TECAB still needs to justify its cost against other minimally invasive coronary revascularization techniques that carry many of the same clinical benefits that TECAB offers. Moreover, as noted above, newer generation, TECAB-specific instruments, which further simplify the operation, must also be developed and introduced to the clinical setting after receiving approval from the appropriate health regulatory bodies.

The conversion rate for TECAB has been trending down since the Göbölös publication \(^{37}\) with many recent studies now suggesting rates <1%. \(^{54}\) Reported operative times have also been decreasing with 20 to 30 cases to overcome the learning curve. \(^{37,55}\) Cross-clamp time and CPB time of 67.9 min and 100.4 min, respectively, were reported in a meta-analysis by Leonard. \(^{38}\)

**Future Outlook**

Robotic cardiac surgery is still in the early development stages, with rapid innovations in equipment and techniques. Improvements in structured training and robotic technology, including stabilizers, connectors, and anastomotic devices that can eliminate endoscopic suturing will lessen the technical difficulty, the learning curve, and operative times. Unfortunately, with the introduction of new and expensive devices and robots, cost is likely to be the biggest barrier against its wide adoption. There needs to be a greater number of thorough cost analysis studies, and a reasonable financial incentive structure for new institutions to adopt and maintain their robotic cardiac surgery programs. Additionally, new technological improvements would mean more variability in the way that TECAB is practiced and also in the training programs that are established across institutions. Standardization of the practice will be an important factor in the development of TECAB. Randomized controlled trials in TECAB in addition to observational studies will need to establish excellent long-term patency, morbidity, and mortality rates. Unless these barriers are addressed, the numbers of RA CABG may continue to decrease, as seen in current usage trends.

**Hybrid Coronary Revascularization**

**Overview**

HCR, first described by Angelini et al. in 1996, \(^{56}\) combines the surgical anastomosis of LIMA to LAD with PCI to non-LAD lesions. LIMA to LAD anastomosis is currently being done with either a MIDCAB, RA-MIDCAB, or a TECAB thereby avoiding a sternotomy. PCI to non-LAD lesions further reduces the invasiveness and technical complexity of graft usage in...
minimally invasive coronary revascularization techniques. HCR only composes 0.48% of the total isolated CABG volume in the United States, and with 358 (50.4%) hospitals having performed HCR between 2009 and 2017, 97.3% of the hospitals performs <1 procedure per year. However, its safety and feasibility are well demonstrated in the literature and appropriately reflected in the current guidelines (Supplemental Table). The consensus regarding HCR today is that the procedure will remain limited to few dedicated centers and specific patients until multicenter, randomized controlled trials demonstrate its efficacy with superior clinical outcomes, and that its barriers to adoption such as learning curve, cost, logistics are addressed.

**Multivessel Grafting**

Determination of the optimal multivessel coronary revascularization strategy rests on multiple factors such as clinical setting, heart function, patient characteristics and preference, comorbidities, graft availability, and most importantly, anatomic factors. CABG has shown to be especially superior to PCI in complex multivessel lesions by large, multicenter, randomized trials such as SYNTAX and FREEDOM. However, compared to well-established therapeutic excellence of LIMA to LAD graft with 10-year patency of greater 90%, venous grafts show inferior results that are being challenged with improvements in drug-eluting stent (DES) replacements. PCI with DES against venous grafts has shown lower rates of failure and re-stenosis, as well as having lower stroke rate, less invasiveness, and shorter recovery when compared with CABG. PCI can now provide a comparable short and midterm outcome to CABG in low-risk patients (low SYNTAX score) and in those with single-vessel disease, which are now reflected in the guidelines.

With respect to whether PCI to a non-LAD artery will be appropriate against multiarterial grafting of multivessel CAD, Royse et al. and Lytle et al. have shown excellent arterial conduit outcomes leading to multiarterial grafts becoming the gold standard in multivessel revascularization. However, confusion around conflicting evidence has led to poor uptake of multiarterial grafts in the United States. Only 10% of CABG are done with >2 arterial grafts and <1% with 3 grafts, whereas over 50% of patients receive >2 arterial grafts in Australia. Thus, the comparison of clinical outcomes between HCR against conventional CABG in the United States should always distinguish the type of graft utilized in conventional CABG. Moreover, the broader adoption of HCR should be considered in the context of lower rates of multiarterial grafts used in the United States.

**Sequence**

The sequence in which HCR is performed today is currently divided into (1) CABG then PCI, (2) PCI then CABG, and (3) simultaneous. Presently, two-thirds of the HCR volume is performed where it is CABG first, followed by PCI. Each approach has its advantages and disadvantages and the choice remains up to the institution’s preference or logistics on a per-patient basis.

CABG then PCI has the advantage of protected LAD territory during the PCI and angiographic confirmation of LIMA-LAD patency during PCI. Its disadvantages include the risk of nephropathy due to surgical intravenous contrast and the potential need for a reoperation due to failure of PCI. In this scenario, aspirin is given before CABG is performed and a second antiplatelet agent is added before PCI for anticoagulation.

PCI then CABG has the advantage of being able to address any stent complications with CABG in addition to managing acute coronary syndrome with PCI to non-LAD lesions. Its disadvantage includes a high risk of ischemia to the unprotected LAD territory, risk of stent thrombosis in the perioperative period due to the hypercoagulable state during subsequent surgery, and risk of bleed with the use of dual antiplatelet in the perioperative period.

Finally, the cases where CABG and PCI are done simultaneously have the advantage of shorter intensive care unit (ICU) and hospital LOS, angiographic confirmation of patency of LIMA-LAD graft, protection of LAD territory, and the ability to repair unsuccessful stents. Their disadvantages include a higher risk of bleeding after surgery due to overlap of anticoagulation and antiplatelet administration, risk of nephropathy due to surgery and intravenous contrast, increased risk of stent thrombosis due to inflammation, and high cost of a hybrid operating room.

**Outcomes**

The variability present in the HCR techniques in the limited number of procedures performed compromise the comparability of clinical outcomes. They include different types of stents, revascularization type, techniques, sequence, and heterogeneity of the study population. Particular attention should be paid to the supposed advantage of HCR, which includes reduced stroke rate due to the elimination of aortic manipulation and CPB, decreased hospital LOS, and earlier recovery. Complete revascularization and reintervention rate should also be considered in the context of replacing venous grafts with DES.

A Society of Thoracic Surgeons database analysis of 950 HCR cases with 33% RA and 30.5% simultaneous HCR revealed no differences in the composite in-hospital mortality and major morbidity between HCR and conventional CABG. This was despite the HCR group having higher cardiovascular risk profiles. Similar results were found in a meta-analysis of observational studies of HCR where there were no significant differences in individual components and composite of death, MI, stroke, or repeat revascularization during hospitalization and at 1-year follow-up. A summarized report of major studies of HCR is shown in Table 3.

There are 2 small randomized controlled trials for the hybrid procedures to date. The Hybrid Revascularization for Multivessel Coronary Artery Disease (HYBRID) trial compared the hybrid procedure against conventional CABG. At a
mean follow-up time of 5.89 years, 9 patients were lost to follow-up with 94 in the HCR arm and 97 in the conventional CABG arm. MIDCAB and Everolimus eluting stents were used for HCR with a mean SYNTAX score of 23. At 5 years, all-cause mortality was similar for HCR and conventional CABG at 6.4% and 9.2%, respectively. Also, no significant difference was observed in the rates of MI, repeat revascularization, stroke, and MACCE. The relatively high repeat revascularization rates of 37.2% for HCR and 45.4% for conventional CABG remain unexplained in the study. Although not statistically significant, the stroke rate was reported to be lower for HCR than conventional CABG at 2.1% and 4.1%. The major bleeding rate was identical at 2.0% and complete revascularization was reported at 77.6% for HCR and 78.2% for conventional CABG. These are higher rates than previously reported for PCI and complete revascularization rate of 50%-60%.

On the other hand, the Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS) trial had 155 patients who were randomized 1:1:1 to hybrid, conventional CABG, and PCI. SYNTAX scores for the groups were between 19.3 and 19.5. At 12 months, mortality was 5.8%, 2.0%, and 3.8%, respectively. Interestingly, the hybrid arm was the only group with the incidence of stroke at 3.8% and repeat revascularization at 1.9%. Major bleeding rates were reported at 9.6% for the hybrid procedure, 20.0% for conventional CABG, and 0% for PCI. The complete revascularization rate was reported higher than previous observational studies and the HYBRID trial at 92.3%, 92%, and 94.3%. The conversion rate was reported at 6.1% for the HYBRID trial and 9.6% for the HREVS trial. Hospital LOS, ICU LOS, and transfusion rates were reported to be significantly shorter for HCR versus conventional CABG in a meta-analysis by Zhu et al. However, hospital LOS was similar.

### Table 3. Summary of Major Hybrid Coronary Revascularization Studies

| Authors            | Patients | Surgical technique | Median follow-up time (y) | Survival at follow-up | Sternotomy conversion | Perioperative stroke (30-d) | LOS (days) | LIMA LAD patency | Complete revascularization | Repeat revascularization |
|--------------------|----------|-------------------|---------------------------|-----------------------|-----------------------|---------------------------|------------|-----------------|---------------------------|-------------------------|
| Retrospective studies          |          |                   |                           |                       |                       |                           |            |                 |                           |                         |                         |
| Halkos et al. (2011)  | 27       | MIDCAB            | 3.2                       | 86.8% (estimated 5-y survival) | NR                    | 0.7%                       | 6.6        | NR              | NR                        | 12.2%                   |                         |
| Bonatti et al. (2012) | 140      | TECAB             | NR                        | 92.9% (5 y)            | NR                    | 9.7%                       | 6.0        | NR              | NR                        |                         |                         |
| Repossini et al. (2013) | 166      | MIDCAB            | 4.5                       | 95.8%                 | NR                    | 2.4%                       | 6.5        | 100% before PCI | Functionally complete, 100% Anatomically incomplete, 16.9% |                         |                         |
| Adams et al. (2014)  | 96       | RA-MIDCAB         | 5                         | 91%                   | 2.1%                  | 1.1%                       | 4.0        | 89.5%           | NR                        | 13%                     |                         |
| Halkos et al. (2014) | 300      | RA-MIDCAB         | NR                        | 98.7% (30-d)          | 2%                    | 1%                         | 5.0        | 97.6%           | NR                        | 4.3%                    |                         |
| Giambruno et al. (2018) | 144     | RA-MIDCAB         | 8                         | 97%                   | 5%                    | 2.1%                       | 4.5        | NR              | NR                        | 9%                     |                         |
| Repossini et al. (2018) | 77      | MIDCAB            | 1.3                       | 100%                  | 1.4%                  | 0%                         | NR         | 100%            | NR                        | 5.2%                    |                         |
| Di Bacco et al. (2019) | 120     | MIDCAB            | 6                         | HCR, 82% Conventional CABG, 82.3% Total arterial CABG, 90.4% | NR                    | 0%                         | 5.3        | NR              | NR                        |                         |                         |
| Kiai et al. (2019)    | 191      | RA-MIDCAB         | 6.9                       | 93.9%                 | 4.2%                  | 1.1%                       | 4.0        | 97.9% at 6 mo   | NR                        | 11.5%                   |                         |
| Hage et al. (2019)    | 147      | RA-MIDCAB         | 8                         | 96%                   | 5%                    | 2.1%                       | 4.5        | NR              | NR                        | 9%                     |                         |
| Prospective studies   |          |                   |                           |                       |                       |                           |            |                 |                           |                         |                         |
| Vassiliades et al. (2009) | 91   | Endoscopicatraumatic CAB | 3.5                | 94%                   | 1%                    | 0%                         | NR         | 98%             | NR                        | 5.5% at 1 y             |                         |
| Bachinski et al. (2012) | 25   | RA-MIDCAB         | 0 mo                      | 100%                  | NR                    | 0%                         | 5.1        | NR              | 86%                       | 0%                     |                         |
| Puskas et al. (2016)  | 200      | Variable          | 1.5                       | 98.5%                 | NR                    | 0%                         | NR         | 75.2%           | 7%                       |                         |                         |
| Song et al. (2016)    | 120      | MIDCAB            | 2.5                       | 97.3%                 | 0%                    | 0%                         | 7.0        | NR              | NR                        | 4.7%                   |                         |
| Tajstra et al. (2018) | 94       | MIDCAB            | 5.9                       | 93.6%                 | NR                    | 2.1%                       | 5.0        | NR              | NR                        | 37.2%                  |                         |
| Ganyukov et al. (2020) | 52     | MIDCAB            | 1                         | 94.2%                 | 9.6%                  | 1.9%                       | 13.8       | 97.9%           | 92.3%                     | 1.9% at 30 d            |                         |
| Esteves et al. (2020) | 40       | MIDCAB            | 2.2                       | 95%                   | NR                    | 0%                         | NR         | NR              | NR                        | 14.5%                  |                         |

Abbreviations: HCR, hybrid coronary revascularization; LAD, left anterior descending artery; LIMA, left internal mammary artery; MIDCAB, minimally invasive direct coronary artery bypass; NR, not reported; PCI, percutaneous coronary intervention; RA, robot-assisted; TECAB, totally endoscopic coronary artery bypass.
between the hybrid and conventional CABG arms at 8.6 ± 4.1 and 8.5 ± 5.2, respectively. It should be noted that hospital LOS for the 9.6% of hybrid procedures that were converted to conventional CABG were still included in the hybrid group.

**Patient Selection**

The current value proposition of HCR lies with a specific set of patients where neither CABG nor PCI alone can effectively provide the best revascularization option for the patient. They include patients unsuitable for CABG due to severe preexisting comorbidities, lack of suitable graft conduits, calcified aorta, tortuous vessels, or chronic total occlusion of distal left main or LAD arteries. The patients would, in turn, need to have non-LAD vessels that are amenable to PCI and distal LAD anatomy suitable for LIMA-LAD graft. Contraindications for HCR include emergency surgery and hemodynamic instability, previous chest surgery, significant obesity, and moderate to severe COPD. When the barriers to its adoption are addressed and excellent long-term outcomes are demonstrated in large randomized trials, HCR may be offered not only as an alternative but also as a primary surgical option for patients who meet the indications.

**Barriers to Adoption**

Technical difficulty is less than that of multivessel MICS CABG or TECAB, as HCR only requires a LIMA-LAD anastomosis. However, off-pump MIDCAB remains a technical challenge for surgeons with results being case-load and surgeon dependent with 50 to 100 cases required to cross 95% reassurance boundary. HCR also carries a logistical challenge of coordinating the revascularization, training the care team, and the planning of hybrid operating rooms in the case of simultaneous HCR.

The cost of HCR was compared to OPCAB in a meta-analysis by Dong et al. that demonstrated increased cost with HCR despite shorter ICU and hospital stay and decreased transfusion rates. Bachinsky et al. also showed higher cost for HCR compared to OPCAB despite lower postoperative cost ($33,984 ± $4,806 vs $27,816 ± $11,172). However, Halkos et al. showed that HCR results in a greater contribution margin for hospitals in comparison to OPCAB possibly due to higher reimbursement in the United States and improved postoperative resource utilization. Adjusted for LOS and predicted risk of mortality score, the study still showed a total contribution margin of $8,771 to be greater for HCR versus OPCAB.

**Future Outlook**

Retrospective observational studies of HCR have demonstrated safety and feasibility, which are reflected in the current guidelines. Larger multicenter trials that can effectively remove the bias associated with smaller trials and observational studies are needed to determine some of the contradicting results seen in the trials to date. Current trials that are in recruiting and active stages are highlighted in Table 4. Within this context, it is important to highlight the CTSN HYBRID trial (NCT03089398), which aimed to randomize patients to either HCR or multivessel PCI with metallic DES in patients with multivessel CAD involving the LAD or left main territories. The trial was stopped given poor patient enrollment. Therefore, the theoretical benefit of decreased stroke rate, lower reintervention rates, and earlier recovery need to be studied further, given the aforementioned barriers to this procedure. Clinical equipoise will not suffice for HCR to gain wide adoption among the surgeons. Finally, HCR also provides an opportunity for advanced hybrid coronary interventions, where both internal mammary arteries can be harvested and grafted minimally invasively and combined with PCI. In the future, this strategy may be indicated for a growing patient population that would benefit from double internal mammary bypass grafts.

**Conclusions**

Since the introduction of CABG, midline sternotomy has been the steadfast approach for coronary revascularization, with excellent clinical outcome and reproducibility. With limitations of stent technology, manifested by inferior long-term results for multivessel disease, CABG will continue to be the gold standard treatment of CAD for the foreseeable future. However, cardiac surgery as a specialty is becoming less invasive with evolving surgical technique supported by innovations in robotic technology and surgical instruments. Recently, there has also been an increase in catheter-based interventions and in some cases, conventional heart operations are being replaced by catheter-based technology. This has resulted in an increase in the demand for minimally invasive interventions. Even an operation with excellent outcome and reproducibility may be perceived by patients and referring physicians as extremely invasive, to a point where an increasing number of patients may accept inferior long-term results over surgical revascularization.

To date, 3 main approaches have been adopted for minimally invasive coronary revascularization techniques: MICS CABG, TECAB, and HCR. All of these strategies are technically challenging and require special logistical considerations, which has resulted in slow and modest uptake among cardiac surgeons around the world. To expand the application of MIS CABG, improvements are required to continue to deliver optimal, precise, and durable results with revascularization. Predicting which minimally invasive technique will gain the greatest traction depends on how each of those approaches overcome their barriers. For MICS CABG, it is the technical difficulty of its multivessel procedure; for TECAB, it is the cost, technical complexity, and logistics of owning and operating a robot; and for HCR, it is the lack of large well-designed trials that show the comparable results of HCR over conventional CABG and potentially superior results to PCI.

Despite the early stage of these techniques, minimally invasive surgical coronary revascularization is a rapidly evolving area that has the potential to reshape the future treatment and management of coronary artery disease. In
addition to larger and well-designed trials that can assess and objectively determine clinical outcomes, future studies should further explore patient recovery status, patient quality of life, cost-benefit analysis, and training strategies. Moreover, to encourage better adoption rates for any of these techniques, it is imperative to not only show superior benefits and outcomes but to also continue to improve instruments that can facilitate training. Finally, there is a real opportunity for large centers to develop specialized programs that focus on minimally invasive coronary surgery. The onus is on the surgical community to spearhead the institution and training of future surgeons who are comfortable and competent in ensuring optimal clinical outcomes for minimally invasive coronary surgery. There is already a precedent in cardiac surgery, with the success of minimally invasive valve surgery, so it is important for surgeons to seize this opportunity and lay the foundations for successful minimally invasive coronary surgery programs.

Table 4. Summary of Current Clinical Trials on HCR

| Status                  | Study title                                                                 | Trial ID         | Intervention                                      | Location                                                                 |
|-------------------------|-----------------------------------------------------------------------------|------------------|---------------------------------------------------|-------------------------------------------------------------------------|
| Completed December 31, 2010 | Coronary Stenting and Coronary Bypass Grafting at the Same Time in a Specialty Built Operating Room | NCT00366015     | Robot-assisted coronary surgical revascularization PCI with drug-eluting stents | The London Health Sciences Centre, University Hospital London, ON, Canada |
| Completed October, 2013 | Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease (POL-MIDES) | NCT01035567     | Hybrid revascularization CABG                     | Silesian Medical University, Silesian Center for Heart Disease Zabrze, Poland |
| Completed September 16, 2017 | The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG (HREV5) | NCT01699048     | Hybrid (MIDCAB + PCI) PCI CABG                  | Research Institute of Complex Issues of Cardiovascular Diseases Kemerovo, Russian Federation |
| Completed December, 2019 | HYbrid CoronAry Revascularization in DiabeticS (HYCARDS)                     | NCT02504762     | HCR Conventional CABG                             | University of Ottawa Heart Institute Ottawa, ON, Canada Multicenter     |
| Active, not recruiting | Hybrid Coronary Revascularization Trial                                       | NCT03089398     | HCR PCI                                          | Faculdade de Medicina da Universidade de São Paulo São Paulo, SP, Brazil |
| Active, not recruiting | Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING for Complex Triple-vessel Disease (MERGING) | NCT02226900     | Hybrid revascularization Conventional CABG        | Aarhus University Hospital, Skejby Aarhus N, Denmark UPMC Pinnacle Harrisburg Harrisburg, PA, USA |
| Active, not recruiting | Coronary Hybrid Revascularization Study                                       | NCT01496664     | Combined CABG and PCI                             | UPMC Pinnacle Harrisburg, PA, USA                                       |
| Recruiting              | A Single-Center Clinical Evaluation of Same Sitting Hybrid Revascularization: Robotic Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention for the Treatment of Coronary Artery Disease | NCT00928356     | Hybrid CABG/PCI Off-pump CABG                   | UPMC Pinnacle Harrisburg, PA, USA                                       |

Abbreviations: CABG, coronary artery bypass grafting; HCR, hybrid coronary revascularization; MIDCAB, minimally invasive direct coronary artery bypass; PCI, percutaneous coronary intervention

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Supplemental Material
Supplemental material for this article is available online.

References
1. Teo KK, Cohen E, Buller C, et al. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/ Canadian Society of Cardiac Surgery position statement on revascularization-multivessel coronary artery disease. *Can J Cardiol* 2014; 30: 1482–1491.
2. Neumann F, Sousa-Uva M and Ahlsson A. ESC/EACTS guidelines on myocardial revascularization. EuroIntervention 2019; 40: 87–165.

3. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: Executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126: 3097–3137.

4. Mohr FW, Morice M-C, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629–638.

5. Farkouh ME, Domanski M, Dangas GD, et al. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM Follow-On Study. J Am Coll Cardiol 2019; 73: 629–638.

6. Giustino G, Serruys PW, Sabik JF, et al. Mortality after repeat revascularization following PCI or CABG for left main disease: the EXCEL trial. JACC Cardiovasc Interv 2020; 13: 375–387.

7. Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet 2016; 388: 2743–2752.

8. Ruel M, Falk V, Farkouh ME, et al. Myocardial revascularization trials. Circulation 2018; 138: 2943–2951.

9. Ruel M. Editorial: coronary artery surgery: a resurgence and new opportunity to serve our patients better. Curr Opin Cardiol 2019; 34: 627.

10. Kipp R, Lehman J, Israel J, et al. Patient preferences for coronary artery bypass graft surgery or percutaneous intervention in multivessel coronary artery disease. Catheter Cardiovasc Interv 2013; 82: 212–218.

11. Kiaii B and Teefy P. Hybrid coronary artery revascularization: a review and current evidence. Innovations 2019; 14: 394–404.

12. Ruel M, Une D, Bonatti J, et al. Minimally invasive coronary artery bypass grafting: is it time for the robot? Curr Opin Cardiol 2013; 28: 639–645.

13. Lapierre H, Chan V and Sohmer B. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg 2011; 40: 804–810.

14. McGinn JT, Usman S, Lapierre H, et al. Minimally invasive coronary artery bypass grafting: dual-center experience in 450 consecutive patients. Circulation 2009; 120(11 Suppl): S78–S84.

15. Chan V, Lapierre H, Sohmer B, et al. Handsewn proximal anastomoses onto the ascending aorta through a small left thoracotomy during minimally invasive coronary artery bypass grafting: a stepwise approach to safety and reproducibility. Semin Thorac Cardiovasc Surg 2012; 24: 79–83.

16. Une D and Sakaguchi T. Initiation and modification of minimally invasive coronary artery bypass grafting. Gen Thorac Cardiovasc Surg 2019; 67: 349–354.

17. Cremer J, Schoettler J, Thiem A, et al. The MIDCAB approach in its various dimensions. HSR Proc Intensive Care Cardiovasc Anesth 2011; 3: 249–253.

18. Rabindranauth P, Burns JG, Vessey TT, et al. Minimally invasive coronary artery bypass grafting is associated with improved clinical outcomes. Innovations 2014; 9: 421–426.

19. Rodriguez ML, Lapiere HR, Sohmer B, et al. Mid-term follow-up of minimally invasive multivessel coronary artery bypass grafting: is the early learning phase detrimental? Innovations 2017; 12: 116–120.

20. Namdar P, Kumar S, Mittal CM, et al. Minimally invasive coronary artery bypass grafting with bilateral internal thoracic arteries: will this be the future? J Thorac Cardiovasc Surg 2018; 155: 190–197.

21. Ruel M, Shariff MA, Lapiere H, et al. Results of the minimally invasive coronary artery bypass grafting angiographic patency study. J Thorac Cardiovasc Surg 2014; 147: 203–209.

22. Une D, Lapiere H, Sohmer B, et al. Can minimally invasive coronary artery bypass grafting be initiated and practiced safely?: a learning curve analysis. Innovations 2013; 8: 403–409.

23. Rabindranauth P, Burns JG, Vessey TT, et al. Minimally invasive coronary artery bypass grafting is associated with improved clinical outcomes. Innovations 2014; 9: 421–426.

24. Ziankou A and Ostrovsky Y. Early and midterm results of no-touch aorta multivessel small thoracotomy coronary artery bypass grafting: a propensity score-matched study. Innovations 2015; 10: 258–267.

25. Rogers CA, Pike K, Angelini GD, et al. An open randomized controlled trial of median sternotomy versus anterolateral left thoracotomy on morbidity and health care resource use in patients having off-pump coronary artery bypass surgery: the Sternotomy Versus Thoracotomy (STET) trial. J Thorac Cardiovasc Surg 2013; 146: 306–316.

26. Guo MH, Wells GA, Glineur D, et al. Minimally Invasive coronary surgery compared to STernotomy coronary artery bypass grafting: The MIST Trial. Contemp Clin Trials 2019; 78: 140–145.

27. Rodriguez M and Ruel M. Minimally invasive multivessel coronary surgery and hybrid coronary revascularization: can we routinely achieve less invasive coronary surgery? Methodist Debakey Cardiovasc J 2016; 12: 14–19.

28. Barsoum EA, Azab B, Shah N, et al. Long-term mortality in minimally invasive compared with sternotomy coronary artery bypass surgery in the geriatric population (75 years and older patients). Eur J Cardiothorac Surg 2015; 47: 862–867.

29. Lamy A, Devereaux PJ, Prabhakaran D, et al. Five-year outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med 2016; 375: 2359–2368.

30. Rodriguez ML, Lapiere HR, Sohmer BF, et al. Repeat revascularization after minimally invasive coronary artery bypass grafting: is it a problem? Innovations 2017; 12: 269–274.
31. Pasrija C, Kon ZN, Ghorbeshi M, et al. Cost and outcome of minimally invasive techniques for coronary surgery using robotic technology. *Innovations* 2018; 13: 282–286.

32. Merkle J, Zerrouk M, Sabashnikov A, et al. Minimally invasive direct coronary artery bypass graft surgery versus percutaneous coronary intervention of the LAD: costs and long-term outcome. *Perfusion* 2019; 34: 323–329.

33. Nishigawa K, Fukui T, Tabata M, et al. V-composite grafting using the right internal thoracic artery grafts anastomosed to aorto-coronary bypass grafts. *Eur J Cardiothorac Surg* 2015; 48: 753–757.

34. Kikuchi K, Une D, Endo Y, et al. Minimally invasive coronary artery bypass grafting using bilateral in situ internal thoracic arteries. *Ann Thorac Surg* 2015; 100: 1082–1084.

35. Loumet D, Carpentier A, d’Attellis N, et al. Endoscopic coronary artery bypass grafting with the aid of robotic assisted instruments. *J Thorac Cardiovasc Surg* 1999; 118: 4–10.

36. Pettinari M, Navarra E, Noirhomme P, et al. The state of robotic cardiac surgery in Europe. *Ann Cardiothorac Surg* 2017; 6: 1–8.

37. Göbölös L, Ramahi J, Obeso A, et al. Robotic totally endoscopic coronary artery bypass grafting: systematic review of clinical outcomes from the past two decades. *Innovations* 2019; 14: 5–16.

38. Leonard JR, Rahouma M, Abouarab AA, et al. Totally endoscopic coronary artery bypass surgery: a meta-analysis of the current evidence. *Int J Cardiol* 2018; 261: 42–46.

39. Cao C, Indraratna P, Doyle M, et al. A systematic review on robotic coronary artery bypass graft surgery. *Ann Cardiothorac Surg* 2016; 5: 530–543.

40. Kitahara H, McCrorey M, Patel B, et al. Benefit of robotic beating-heart totally endoscopic coronary artery bypass in octogenarians. *Innovations* 2019; 14: 531–536.

41. Balkhy HH, Wann LS, Krienbring D, et al. Integrating coronary anastomotic connectors and robotics toward a totally endoscopic beating heart approach: review of 120 cases. *Ann Thorac Surg* 2011; 92: 821–827.

42. Srivastava S, Gadasalli S, Agusala M, et al. Robotic assisted beating heart totally endoscopic coronary artery bypass (TECAB). Is there a future? *Innovations* 2008; 3: 52–58.

43. Kitahara H, McCrorey M, Patel B, et al. Does robotic beating heart connector totally endoscopic coronary artery bypass bridge the gender gap in coronary bypass surgery? *Innovations* 2018; 13: 35–39.

44. Giambruno V, Chu MW, Fox S, et al. Robotic-assisted coronary artery bypass surgery: an 18-year single-centre experience. *Int J Med Robot* 2018; 14: e1891.

45. Kitahara H, Patel B, McCrorey M, et al. Is robotic beating heart totally endoscopic coronary artery bypass feasible for BMI > 35 morbidly obese patients? *Int J Med Robot* 2018; 14: e1911.

46. Lee JD, Bonaros N, Hong PT, et al. Factors influencing hospital length of stay after robotic totally endoscopic coronary artery bypass grafting. *Ann Thorac Surg* 2013; 95: 813–818.

47. Kitahara H, Wehman B and Balkhy HH. Can robotic-assisted surgery overcome the risk of mortality in cardiac reoperation? *Innovations* 2018; 13: 438–444.

48. Balkhy HH, Nisivaco S, Kitahara H, et al. Robotic beating heart totally endoscopic coronary artery bypass in higher-risk patients: can it be done safely? *Innovations* 2018; 13: 108–113.

49. Bonaros N, Schachner T, Wiedemann D, et al. Quality of life improvement after robotically assisted coronary artery bypass grafting. *Cardiology* 2009; 114: 59–66.

50. Bonatti J, Lee JD, Bonaros N, et al. Robotic totally endoscopic multivessel coronary artery bypass grafting: procedure development, challenges, results. *Innovations* 2012; 7: 3–8.

51. Barbash GI and Glied SA. New technology and health care costs—the case of robot-assisted surgery. *N Engl J Med* 2010; 363: 701–704.

52. Moscarelli M, Harling L, Ashrafian H, et al. Challenges facing totally endoscopic robotic coronary artery bypass grafting. *Int J Med Robot* 2015; 11: 18–29.

53. Leyvi G, Schechter CB, Sehgal S, et al. Comparison of index hospitalization costs between robotic CABG and conventional CABG: implications for hybrid coronary revascularization. *J Cardiothorac Vasc Anesth* 2016; 30: 12–18.

54. Kitahara H, Nisivaco S and Balkhy HH. Graft patency after totally endoscopic coronary artery bypass in higher-risk patients: can it be done safely? *Int J Med Robot* 2018; 14: e1891.

55. Cheng N, Gao C, Yang M, et al. Analysis of the learning curve for beating heart, totally endoscopic, coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2014; 148: 1832–1836.

56. Angelini GD, Wilde P, Salerno TA, et al. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation. *Lancet* 1996; 347: 757–758.

57. Harskamp RE, Brennan JM, Xian Y, et al. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the Society of Thoracic Surgeons Adult Cardiac Database. *Circulation* 2014; 130: 872–879.

58. Lowenstein A, Wu J, Bradley SM, et al. Current landscape of hybrid revascularization: a report from the NCDR CathPCI registry. *Am Heart J* 2019; 215: 167–177.

59. Holzhey DM, Jacobs S, Walther T, et al. Cumulative sum failure analysis for eight surgeons performing minimally invasive direct coronary artery bypass. *J Thorac Cardiovasc Surg* 2007; 134: 663–669.

60. Pick AW, Orszulak TA, Anderson BJ, et al. Single versus bilateral internal mammary artery grafts: 10-year outcome analysis. *Ann Thorac Surg* 1997; 64: 599–605.

61. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996; 335: 217–225.

62. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 1996; 28: 616–626.

63. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. *J Am Coll Cardiol* 1996; 28: 616–626.
internal mammary artery and venous autograft at 18 to 20 years of follow-up. *J Thorac Cardiovasc Surg* 1994; 107: 657–662.

65. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. *JAMA* 2005; 294: 2446–2454.

66. Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009; 360: 961–972.

67. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. *Circulation* 2003; 107: 38–42.

68. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. *J Am Coll Cardiol* 2009; 53: 2324–2331.

69. Lytle BW, Blackstone EH, Loop FD, et al. Two internal thoracic artery grafts are better than one. *J Thorac Cardiovasc Surg* 1999; 117: 855–872.

70. Royse AG, Brennan AP, Ou-Young J, et al. 21-year survival of left internal mammary artery-radial artery-Y graft. *J Am Coll Cardiol* 2018; 72: 1332–1340.

71. Schwann TA, Tatoulis J, Puskas J, et al. Worldwide trends in multi-arterial coronary artery bypass grafting surgery 2004-2014: a tale of 2 continents. *Semin Thorac Cardiovasc Surg* 2017; 29: 273–280.

72. Ejoifor JI, Leacche M and Byrne JG. Robotic CABG and hybrid approaches: the current landscape. *Prog Cardiovasc Dis* 2015; 58: 356–364.

73. Levy G, Dabas A and Leff JD. Hybrid coronary revascularization - current state of the art. *J Cardiothorac Vasc Anesth* 2019; 33: 3437–3445.

74. Lison S, Weiss G, Spannagl M, et al. Postoperative changes in procoagulant factors after major surgery. *Blood Coagul Fibrinolysis* 2011; 22: 190–196.

75. Panoulas VF, Colombo A, Marginato A, et al. Hybrid coronary revascularization: promising, but yet to take off. *J Am Coll Cardiol* 2015; 65: 85–97.

76. Kim JH, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. *Am Heart J* 2008; 156: 886–892.

77. Harskamp RE, Bagai A, Halkos ME, et al. Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery: a meta-analysis of 1,190 patients. *Am Heart J* 2014; 167: 585–592.

78. Zhu P, Zhou P, Sun Y, et al. Hybrid coronary revascularization versus coronary artery bypass grafting for multivessel coronary artery disease: systematic review and meta-analysis. *J Cardiothorac Vasc Surg* 2015; 10: 63.

79. Gąsior M, Zembala MO, Tajstra M, et al. Hybrid revascularization for multivessel coronary artery disease. *JACC Cardiovasc Interv* 2014; 7: 1277–1283.

80. Park S-J, Ahn J-M, Kim Y-H, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. *N Engl J Med* 2015; 372: 1204–1212.

81. Ganyukov V, Kochergin N, Shilov A, et al. Randomized clinical trial of surgical vs. percutaneous vs. hybrid revascularization in multivessel coronary artery disease: residual myocardial ischemia and clinical outcomes at one-year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS). *J Interv Cardiol* 2020; 2020: 5458064.

82. Rosenblum JM, Harskamp RE, Hoedemaker N, et al. Hybrid coronary revascularization versus coronary artery bypass surgery with bilateral or single internal mammary artery grafts. *J Thorac Cardiovasc Surg* 2016; 151: 1081–1089.

83. Kayatta MO, Halkos ME and Puskas JD. Hybrid coronary revascularization for the treatment of multivessel coronary artery disease. *Ann Cardiothorac Surg* 2018; 7: 500–505.

84. Dong L, Kang Y-K and X-G A. Short-term and mid-term clinical outcomes following hybrid coronary revascularization versus off-pump coronary artery bypass: a meta-analysis. *Arq Bras Cardiol* 2018; 110: 321–330.

85. Bachinsky WB, Abdelalaim M, Boga G, et al. Comparative study of same sitting hybrid coronary artery revascularization versus off-pump coronary artery bypass in multivessel coronary artery disease. *J Interv Cardiol* 2012; 25: 460–468.

86. Halkos ME, Ford L, Peterson D, et al. The impact of hybrid coronary revascularization on hospital costs and reimbursemens. *Ann Thorac Surg* 2014; 97: 1610–1616.

87. Gaudino M, Bakaeen F, Davierwala P, et al. New strategies for surgical myocardial revascularization. *Circulation* 2018; 138: 2160–2168.

88. Nambiar P, Kumar S, Mittal CM, et al. Outcomes of bilateral internal thoracic arteries in minimally invasive coronary artery bypass grafting with analogy to the SYNTAX trial. *Innovations* 2019; 14: 227–235.

89. de Cannière D, Wimmer-Greinecker G, Cichon R, et al. Feasibility, safety, and efficacy of totally endoscopic coronary artery bypass grafting for the treatment of multivessel coronary artery disease. *J Thorac Cardiovasc Surg* 2007; 134: 710–716.

90. Bonatti J, Schachner T, Bonaros N, et al. Effectiveness and safety of total endoscopic left internal mammary artery bypass graft to the left anterior descending artery. *Am J Cardiol* 2009; 104: 1684–1688.

91. Srivastava S, Gadasalli S, Agusala M, et al. Beating heart totally endoscopic coronary artery bypass. *Ann Thorac Surg* 2010; 89: 1873–1880.

92. Dhawan R, Roberts JD, Wroblewski K, et al. Multivessel beating heart robotic myocardial revascularization increases morbidity and mortality. *J Thorac Cardiovasc Surg* 2012; 143: 1056–1061.

93. Bonaros N, Schachner T, Lehr E, et al. Five hundred cases of robotic totally endoscopic coronary artery bypass grafting: predictors of success and safety. *Ann Thorac Surg* 2013; 95: 803–812.

94. Weidinger F, Schachner T, Bonaros N, et al. Predictors and consequences of postoperative atrial fibrillation following...
robotic totally endoscopic coronary bypass surgery. *Eur J Cardiothorac Surg* 2014; 45: 318–322.

95. Yang M, Wu Y, Wang G, et al. Robotic total arterial off-pump coronary artery bypass grafting: seven-year single-center experience and long-term follow-up of graft patency. *Ann Thorac Surg* 2015; 100: 1367–1373.

96. Halkos ME, Rab ST, Vassiliades TA, et al. Hybrid coronary revascularization versus off-pump coronary artery bypass for the treatment of left main coronary stenosis. *Ann Thorac Surg* 2011; 92: 2155–2160.

97. Bonatti JO, Zimrin D, Lehr EJ, et al. Hybrid coronary revascularization using robotic totally endoscopic surgery: perioperative outcomes and 5-year results. *Ann Thorac Surg* 2012; 94: 1920–1926.

98. Repossini A, Tespili M, Saino A, et al. Hybrid revascularization in multivessel coronary artery disease. *Eur J Cardiothorac Surg* 2013; 44: 288–294.

99. Adams C, Burns DJP, Chu MWA, et al. Single-stage hybrid coronary revascularization with long-term follow-up. *Eur J Cardiothorac Surg* 2014; 45: 438–443.

100. Halkos ME, Walker PF, Vassiliades TA, et al. Clinical and angiographic results after hybrid coronary revascularization. *Ann Thorac Surg* 2014; 97: 484–490.

101. Giambruno V, Jones P, Khalil F, et al. Hybrid coronary revascularization versus on-pump coronary artery bypass grafting. *Ann Thorac Surg* 2018; 105: 1330–1335.

102. Repossini A, Di Bacco L, Rosati F, et al. Hybrid coronary revascularization versus percutaneous strategies in left main stenosis: a propensity match study. *J Cardiovasc Med* 2018; 19: 253–260.

103. Di Bacco L, Repossini A, Tespili M, et al. Long-term follow-up of total arterial versus conventional and hybrid myocardial revascularization: a propensity score matched analysis. *Cardiovasc Revasc Med* 2019; 20: 22–28.

104. Hage A, Giambruno V, Jones P, et al. Hybrid coronary revascularization versus off-pump coronary artery bypass grafting: comparative effectiveness analysis with long-term follow-up. *J Am Heart Assoc* 2019; 8: e014204.

105. Song Z, Shen L, Zheng Z, et al. One-stop hybrid coronary revascularization versus off-pump coronary artery bypass in patients with diabetes mellitus. *J Thorac Cardiovasc Surg* 2016; 151: 1695–1701.

106. Vassiliades TA, Kilgo PD, Douglas JS, et al. Clinical outcomes after hybrid coronary revascularization versus off-pump coronary artery bypass: a prospective evaluation. *Innovations* 2009; 4: 299–306.

107. Puskas JD, Halkos ME, DeRose JJ, et al. Hybrid coronary revascularization for the treatment of multivessel coronary artery disease: a multicenter observational study. *J Am Coll Cardiol* 2016; 68: 356–365.

108. Tajstra M, Hrapkowicz T, Hawranek M, et al. Hybrid coronary revascularization in selected patients with multivessel disease: 5-year clinical outcomes of the prospective randomized pilot study. *JACC Cardiovasc Interv* 2018; 11: 847–852.

109. Esteves V, Oliveira MAP, Feitosa FS, et al. Late clinical outcomes of myocardial hybrid revascularization versus coronary artery bypass grafting for complex triple-vessel disease: long-term follow-up of the randomized MERGING clinical trial. *Catheter Cardiovasc Interv* 2021; 97: 259–264.